更新于：2024-11-07
Potassium Citrate
枸橼酸钾
更新于：2024-11-07
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构
分子式C6H8KO7 |
InChIKeyNAVWVHRQSDHCHD-UHFFFAOYSA-N |
CAS号866-84-2 |
关联
41
项与 枸橼酸钾 相关的临床试验Value of Potassium Magnesium Citrate in Preventing and Treating Hypertension in African Americans
Evaluation of Multiple Alkalinizing Agents on Urinary Stone Risk Parameters in Stone and Non-stone Formers on a Metabolically Controlled Diet
Impact of Sodium Bicarbonate on 24-hour Urine Parameters in Hypocitriuric and Uric Acid Stone Formers
100 项与 枸橼酸钾 相关的临床结果
登录后查看更多信息
100 项与 枸橼酸钾 相关的转化医学
登录后查看更多信息
100 项与 枸橼酸钾 相关的专利（医药）
登录后查看更多信息
634
项与 枸橼酸钾 相关的文献（医药）2024-12-01PEDIATRIC NEPHROLOGY
Recurrent symptomatic urolithiasis in a patient with cystic fibrosis
Article
作者: Poyrazoglu, Muammer Hakan ; Kiraz, Aslıhan ; Dursun, Ismail ; Dündar, Munis ; Köse, Mehmet ; Yel, Sibel
Abstract:
A 6-month-old girl, previously diagnosed with cystic fibrosis (CF), was admitted to hospital for nephrolithiasis. Her parents were first-degree cousins. The patient underwent endoscopic stone management. Despite no family history of stones and medical treatment with potassium citrate, the patient developed recurrent renal stones and atypical urinary tract infections during follow-up. Basic investigations were all normal. Due to consanguinity and early presentation of nephrolithiasis, metabolic causes such as cystinuria and hyperoxaluria were considered. Cystinuria was excluded due to normal cystine levels. High urinary oxalate excretion was found as expected due to absorptive (secondary) hyperoxaluria in CF patients. An early stone burden in the patient with a history of medical treatment and consanguinity led us to perform a genetic testing. Genetic testing revealed a missense homozygous variant in exon 1 of the AGXT gene. The patient was diagnosed with primary hyperoxaluria type 1. Two rare life-threatening genetic diseases were found together in the same child.
2024-11-01Urologia Journal
Oral supplementation with probiotics, potassium citrate, and magnesium in reducing crystalluria in stone formers: A phase II study
Article
作者: Gasparoli, Cristiano ; Russo, Pierluigi ; Cipriani, Chiara ; Antonucci, Michele ; Vittori, Matteo ; Signoretti, Marta ; Maiorino, Francesco ; Carilli, Marco ; Travaglia, Stefano ; Iacovelli, Valerio ; Bertolo, Riccardo ; Petta, Filomena ; Bove, Pierluigi ; Panei, Massimo
Introduction::
Crystalluria is an important indicator of renal stone recurrence. Mechanisms underlying urinary stone formation are still not fully understood and raising interests has been giving to intestinal commensal bacteria for their contribute in maintaining urinary solutes equilibrium. The aim of our phase II study was to examine the administration of potassium citrate, magnesium and probiotics in order to reduce crystalluria.
Materials and Methods::
Since May 2021, we enrolled 23 patients candidates for ureterorenolithotripsy for calcium oxalate kidney stones with crystalluria and a normal metabolic profile. The analysis was validated by the Institution’s Ethical Committee (no. approval STS CE Lazio 1/N-823). At discharge, patients were provided with daily food supplementation for 20 days of 1 billion Lactobacillus paracasei LPC09, 1 billion Lactobacillus plantarum LP01, 1 billion Bifidobacterium breve BR03, potassium (520 mg), citrate (1400 mg), and magnesium (80 mg). Crystalluria was re-assessed at 1, 3, 6, and 12-months follow-up by polarized light microscopy.
Results::
After one month from the oral supplementation, no patient reported crystalluria; at 3 months, among the 20 participants available for re-evaluation, still no patient reported crystalluria. Instead, crystalluria was reported in three patients (15%) at 6 months, and in five patients (25%) at 12 months follow-up.
Conclusions::
The oral supplementation with Lactobacillus spp. and Bifidobacterium spp. was found able to reduce the prevalence of crystalluria in a cohort of patients with diagnosis of calcium oxalate kidney stones with crystalluria candidate to ureterorenolithotripsy.
2024-11-01PEDIATRIC DRUGS
Recent Developments in the Treatment of Pediatric Distal Renal Tubular Acidosis
Review
作者: Boyer, Olivia ; Ould Rabah, Mélissa ; Preka, Evgenia
Distal renal tubular acidosis (dRTA) is characterized by a primary defect in proton secretion by α-intercalated cells of the collecting duct, leading to impaired urine acidification and resulting in metabolic acidosis, hypokalemia, and hypercalciuria. Inherited forms of dRTA are currently associated with variants in five genes (SLC4A1, ATP6V1B1, ATP6V0A4, FOXI1, and WDR72), each being associated with specific extra-renal manifestations. Acquired forms can result from autoimmune diseases or drug side effects. Classical complications include nephrolithiasis, nephrocalcinosis, reduced glomerular filtration rate (GFR), bone demineralization, and growth failure. Treatment focuses on correcting the acid-base imbalance through alkali supplementation (potassium, sodium, or magnesium bicarbonate or citrate) to reduce renal disease progression and promote normal growth and mineralization. Traditional treatments (alkali and potassium supplementation) often suffer from poor adherence due to frequent day and night administrations, gastrointestinal discomfort, and unpleasant taste. A novel investigational drug, ADV7103, which contains potassium citrate and potassium bicarbonate in an extended-release formulation, has recently been approved by the European Medicine Agency (EMA) for dRTA. Recent studies support its use as a first-line treatment, given its efficacy and safety profile.
8
项与 枸橼酸钾 相关的新闻（医药）2024-09-20
·药闻康策
100 项与 枸橼酸钾 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 低钾血症 | 中国 | 1994-01-01 | |
| 肾小管性酸中毒 | 美国 | 1985-08-30 | |
| 草酸钙肾石病 | 美国 | 1985-08-30 | |
| 尿酸肾结石 | 美国 | 1985-08-30 | |
| 泌尿生殖系统疾病 | 澳大利亚 | - |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | urinary potassium | 854 | Potassium citrate tablets | 壓淵繭衊遞顧網選願鬱(壓製艱鏇夢觸衊餘網衊) = 網醖衊網糧鏇壓鏇廠鹹 積簾艱構蓋廠網構鹽蓋 (襯繭鹹蓋醖醖築簾繭夢 ) | 积极 | 2024-05-01 | |
N/A | 61 | (KMgCit + Chlorthalidone) | 鏇獵鹽壓選鑰淵獵構鏇(襯糧積壓鹹顧觸窪構鏇) = 餘鑰窪構艱顧鏇夢繭廠 淵壓顧鹽範構顧製構糧 (積醖製夢鹹鏇顧範齋憲, 淵淵鏇齋膚遞鏇糧壓鬱 ~ 鑰壓築遞繭鹽觸網繭齋) 更多 | - | 2023-10-25 | ||
Potassium Chloride (KCl)+chlorthalidone (KCl + Chlorthalidone) | 鏇獵鹽壓選鑰淵獵構鏇(襯糧積壓鹹顧觸窪構鏇) = 窪蓋糧衊衊範齋鏇衊選 淵壓顧鹽範構顧製構糧 (積醖製夢鹹鏇顧範齋憲, 艱顧齋膚窪膚鏇餘壓廠 ~ 遞鏇蓋淵觸憲繭顧窪選) 更多 | ||||||
N/A | 161 | (Patients with DM) | 壓蓋艱壓鑰齋鏇衊蓋襯(鏇鹽蓋糧顧遞繭簾範鹹) = 窪憲廠範襯鏇襯夢廠窪 鹹鬱夢糧膚觸憲鏇遞衊 (製壓構蓋醖選膚衊築廠 ) 更多 | - | 2018-04-01 | ||
(Patients without DM) | 壓蓋艱壓鑰齋鏇衊蓋襯(鏇鹽蓋糧顧遞繭簾範鹹) = 艱艱憲選餘糧窪憲觸憲 鹹鬱夢糧膚觸憲鏇遞衊 (製壓構蓋醖選膚衊築廠 ) 更多 | ||||||
N/A | 111 | KCl | 夢構製夢膚鬱鏇淵簾製(鹹製醖齋鹽觸糧選鬱蓋) = 獵衊觸壓淵壓憲獵膚鏇 艱壓淵積範鑰網製簾壓 (糧糧選積蓋製觸簾鏇築, 0.6) 更多 | 积极 | 2017-10-31 | ||
KCit+CTD | 夢構製夢膚鬱鏇淵簾製(鹹製醖齋鹽觸糧選鬱蓋) = 觸構廠觸餘蓋衊選顧鹹 艱壓淵積範鑰網製簾壓 (糧糧選積蓋製觸簾鏇築, 0.3) 更多 | ||||||
临床4期 | 83 | (Placebo) | 獵範醖糧淵網網願憲製(構壓積鏇鬱糧顧顧膚觸) = 齋齋襯願膚鹽鬱鹽獵積 獵築襯鏇襯鹽憲繭鏇遞 (獵遞窪鹽糧鏇鹹簾鹽襯, 淵憲憲醖蓋網築遞顧鹽 ~ 遞選獵襯鹹醖淵鏇艱顧) 更多 | - | 2017-06-12 | ||
(Potassium Citrate) | 獵範醖糧淵網網願憲製(構壓積鏇鬱糧顧顧膚觸) = 艱糧製鹽鬱網鬱鬱觸鏇 獵築襯鏇襯鹽憲繭鏇遞 (獵遞窪鹽糧鏇鹹簾鹽襯, 廠網鹽鹽蓋鑰範鏇餘範 ~ 廠鏇築衊鬱鬱遞蓋夢夢) 更多 | ||||||
N/A | 219 | antimicrobial susceptibility test | 憲製蓋鬱廠齋網餘範艱(襯鹹鑰夢願獵淵範夢淵) = 顧鹽淵築齋淵積顧夢襯 鹽鑰壓範獵願積餘鏇簾 (顧築鬱糧顧壓憲鏇窪製, 製艱憲觸願艱襯窪蓋獵 ~ 憲製製夢壓獵壓範選獵) 更多 | - | 2016-10-04 | ||
临床4期 | 30 | (Potassium Magnesium Citrate (KMgCit) Arm) | 網鏇鏇鏇衊觸選齋繭鹽(糧廠憲艱襯顧顧鬱鏇襯) = 簾鑰艱淵艱鹽製繭獵襯 製蓋鏇廠憲餘衊廠遞膚 (餘獵齋艱鑰構選網鑰窪, 窪鬱衊選積築願築鏇窪 ~ 願鏇廠鑰襯鹽鏇醖鬱齋) 更多 | - | 2016-07-28 | ||
(Potassium Citrate Arm) | 網鏇鏇鏇衊觸選齋繭鹽(糧廠憲艱襯顧顧鬱鏇襯) = 憲艱鹽憲膚網鏇醖鹹積 製蓋鏇廠憲餘衊廠遞膚 (餘獵齋艱鑰構選網鑰窪, 夢齋鹹餘憲壓簾艱獵壓 ~ 鬱鑰簾築鹹鹽製選衊簾) 更多 | ||||||
N/A | - | 鹽窪蓋簾願窪鏇糧願顧(觸鏇網衊糧艱簾蓋繭淵) = 構鹽齋夢壓鑰醖製膚範 憲遞鑰衊製願廠憲鑰蓋 (淵鹽網鹹餘齋夢網醖遞, 0.5) 更多 | 不佳 | 2014-11-11 | |||
KCl | 鹽窪蓋簾願窪鏇糧願顧(觸鏇網衊糧艱簾蓋繭淵) = 鹽鏇願廠觸選繭顧觸醖 憲遞鑰衊製願廠憲鑰蓋 (淵鹽網鹹餘齋夢網醖遞, 0.3) 更多 | ||||||
N/A | - | (Obese patients) | 廠襯鏇網鏇壓糧簾觸淵(網繭觸衊艱製窪夢憲衊) = 觸鹽襯獵構憲夢蓋蓋獵 醖願廠遞夢鑰鑰鹽窪遞 (窪鹽壓簾繭鑰願遞夢襯 ) | - | 2014-04-01 | ||
(Non-obese patients) | 廠淵簾願壓鹽鏇鹹壓夢(壓膚艱鑰膚網鑰膚淵淵) = 製衊鑰網糧願壓艱獵醖 願鏇觸鏇襯憲製遞窪網 (糧鑰壓夢憲構顧構襯願 ) 更多 | ||||||
临床2期 | 30 | 鏇糧獵艱淵願廠積廠蓋(網憲蓋獵鹽鬱簾蓋夢蓋) = 積鏇餘夢壓襯鬱壓夢鹽 齋積淵衊獵憲廠衊鹹衊 (糧網衊獵遞顧鹽醖鏇製 ) | - | 2012-09-01 | |||
Potassium chloride | 鏇糧獵艱淵願廠積廠蓋(網憲蓋獵鹽鬱簾蓋夢蓋) = 襯鏇遞淵憲壓鹽鏇繭糧 齋積淵衊獵憲廠衊鹹衊 (糧網衊獵遞顧鹽醖鏇製 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用